JPMorgan lowered the firm's price target on Exponent to $95 from $100 and keeps an Overweight rating on the shares. The firm updated models in the North American small-cap industrials sector. The group is "undergoing a strategic rebalance, driven by evolving market dynamics and sector-specific growth opportunities," the analyst tells investors in a research note.
